Geron (NASDAQ:GERN) Rating Reiterated by Wedbush

Geron (NASDAQ:GERN - Get Free Report)'s stock had its "outperform" rating reissued by investment analysts at Wedbush in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $6.00 price objective on the biopharmaceutical company's stock. Wedbush's price target would indicate a potential upside of 74.42% from the company's current price.

GERN has been the topic of a number of other reports. The Goldman Sachs Group raised their price objective on Geron from $4.00 to $5.00 and gave the company a "buy" rating in a research note on Friday, March 15th. Needham & Company LLC lifted their price target on shares of Geron from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Friday, March 15th.

Geron Stock Up 0.3 %

NASDAQ GERN traded up $0.01 during trading on Wednesday, reaching $3.44. The company's stock had a trading volume of 12,912,593 shares, compared to its average volume of 11,121,710. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $1.88 billion, a PE ratio of -10.58 and a beta of 0.62. Geron has a 1-year low of $1.64 and a 1-year high of $3.73. The business has a 50-day moving average price of $2.47 and a 200-day moving average price of $2.15.

Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Geron had a negative net margin of 77,691.14% and a negative return on equity of 63.33%. The business had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. During the same quarter in the previous year, the business earned ($0.10) EPS. Geron's quarterly revenue was down 77.7% compared to the same quarter last year. On average, research analysts forecast that Geron will post -0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Geron

A number of institutional investors have recently made changes to their positions in GERN. RA Capital Management L.P. increased its holdings in shares of Geron by 46.5% during the 3rd quarter. RA Capital Management L.P. now owns 46,202,425 shares of the biopharmaceutical company's stock worth $97,949,000 after purchasing an additional 14,657,619 shares during the period. Wellington Management Group LLP increased its stake in Geron by 3,730.2% during the first quarter. Wellington Management Group LLP now owns 10,974,066 shares of the biopharmaceutical company's stock valued at $23,814,000 after acquiring an additional 10,687,554 shares during the period. FMR LLC raised its holdings in Geron by 4,315.3% in the 1st quarter. FMR LLC now owns 8,142,625 shares of the biopharmaceutical company's stock valued at $17,669,000 after acquiring an additional 7,958,208 shares in the last quarter. Vivo Capital LLC lifted its position in shares of Geron by 46.1% in the 4th quarter. Vivo Capital LLC now owns 24,143,681 shares of the biopharmaceutical company's stock worth $50,943,000 after acquiring an additional 7,619,047 shares during the period. Finally, State Street Corp grew its holdings in shares of Geron by 29.7% during the 1st quarter. State Street Corp now owns 25,557,601 shares of the biopharmaceutical company's stock worth $55,460,000 after purchasing an additional 5,845,412 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.